Radiation therapy of inoperable localized prostate carcinoma: an assessment of tumor response and complications.
D000230:Adenocarcinoma / Q000188:drug therapy / Q000532:radiotherapy*; D000368:Aged; D003037:Cobalt Radioisotopes; D004967:Estrogens / Q000627:therapeutic use; D005500:Follow-Up Studies; D006417:Hematuria / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011349:Proctitis / Q000209:etiology; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D011832:Radiation Injuries; D011867:Radioisotope Teletherapy / Q000009:adverse effects; D011879:Radiotherapy Dosage; D011882:Radiotherapy, High-Energy / Q000009:adverse effects; D012007:Rectum / Q000528:radiation effects; D013997:Time Factors; D014521:Urethra / Q000528:radiation effects; D014525:Urethral Stricture / Q000209:etiology; D001743:Urinary Bladder / Q000528:radiation effects; D001745:Urinary Bladder Diseases / Q000209:etiology; D014546:Urinary Catheterization / Q000009:adverse effects; D014552:Urinary Tract Infections / Q000150:complications
D003037:Cobalt Radioisotopes; D004967:Estrogens